ArticlePloS one2026
PEG-fusion of viable sciatic nerve isografts restores axonal structure and behavioral recovery after segmental-loss sciatic nerve injuries in Lewis rats.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Segmental-loss peripheral nerve injuries (SL-PNIs) often produce severe deficits in sensory/motor functions and voluntary behaviors. The current gold standard for repair is neurorrhaphy of a cable autograft that (1) produces donor site morbidity; (2) results in rapid Wallerian degeneration (WD) of severed distal nerve segments; (3) relies on slow (1-2 mm/day) axonal regeneration; (4) does not prevent atrophy of denervated muscles and sensory structures; and (5) results in poor to non-existent recovery of sensory/motor functions and voluntary behaviors, especially with longer segmental-loss gaps and/or with denervated targets located rather distal to a proximal SL-PNI. Our study used genetically identical Lewis rats as a model system for isograft transplants. Neurorrhaphy of viable peripheral nerve isografts (VPNIs) of 5- or 10-mm length was performed to repair sciatic SL-PNIs of 4- or 8-mm gap length, respectively. Animals were repaired with a set of well-specified solutions that did (PEG-fusion group) or did not (Negative Control [NC] group) contain 50% w/w 3.35 kDa polyethylene glycol (PEG), an axolemmal fusogen at that specific weight and concentration. We also examined the effects of locally applied FK506 on 10-mm VPNI repairs both with and without PEG-fusion. We hypothesized that PEG-fusion groups would show better axonal morphology and behavioral recovery, as assessed by the Sciatic Functional Index (SFI), compared to NC groups regardless of the gap length. We also hypothesized that FK506 would improve the effects of PEG-fusion by reducing inflammation. Our data showed that PEG-fused VPNI groups had significantly larger axonal diameters and lower g-ratios, less WD, and better SFI scores compared to NC groups regardless of the gap lengths for SL-PNIs. However, localized FK506 treatment only transiently improved axonal regeneration and impaired long-term SFI behavioral recovery, which is the most important measure of successful repairs. In conclusion, PEG-fusion repair technologies show great potential for improving clinical treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.